Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Filing Details

Accession Number:
Form Type:
Zero Holdings:
Publication Time:
2019-01-18 16:32:23
Reporting Period:
Accepted Time:
2019-01-18 16:32:23
Original Submission Date:
SEC Url:
Form 4 Filing
Cik Name Symbol Sector (SIC) IRS No
1674416 Crispr Therapeutics Ag CRSP () 4/A
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1252524 Von Kurt Emster C/o Crispr Therapeutics, Inc.,
610 Main Street
Cambridge MA 02139
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Shares Disposition 2018-12-18 62,925 $29.70 1,171,268 No 4 S Indirect See Footnote
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Indirect See Footnote
  1. This amended Form 4 is being filed to correct the number of shares sold on December 18, 2018 and the number of shares beneficially owned following the transaction.
  2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.18 to $30.62 per share, inclusive.
  3. The Reporting Person undertakes to provide to Issuer any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein.
  4. Shares are held by ABV VI. Abingworth LLP is the investment manager of ABV VI and has been delegated with all investment and dispositive power over the securities held by ABV VI. Reporting Person is a member of the investment committee of Abingworth LLP, which approves investment and voting decisions by a majority vote, and no individual member has the sole control or voting power over the shares held by ABV VI.
  5. From time to time, the investment committee may delegate investment and voting authority over certain securities held by ABV VI and ABE to employees of Abingworth subject to the supervision and oversight of the investment committee, including any limits on such authority imposed by the investment committee in its discretion and the right of the investment committee to revoke such authority at any time. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any.